Loading…
Novel and Selective Partial Agonists of 5-HT3 Receptors. 2. Synthesis and Biological Evaluation of Piperazinopyridopyrrolopyrazines, Piperazinopyrroloquinoxalines, and Piperazinopyridopyrroloquinoxalines
In continuation of our previous work on piperazinopyrrolothienopyrazine derivatives, three series of piperazinopyridopyrrolopyrazines, piperazinopyrroloquinoxalines, and piperazinopyridopyrroloquinoxalines were prepared and evaluated as 5-HT3 receptor ligands. The chemical modifications performed wi...
Saved in:
Published in: | Journal of medicinal chemistry 1997-06, Vol.40 (12), p.1808-1819 |
---|---|
Main Authors: | , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | |
container_end_page | 1819 |
container_issue | 12 |
container_start_page | 1808 |
container_title | Journal of medicinal chemistry |
container_volume | 40 |
creator | Prunier, Hervé Rault, Sylvain Lancelot, Jean-Charles Robba, Max Renard, Pierre Delagrange, Philippe Pfeiffer, Bruno Caignard, Daniel-Henri Misslin, René Hamon, Michel |
description | In continuation of our previous work on piperazinopyrrolothienopyrazine derivatives, three series of piperazinopyridopyrrolopyrazines, piperazinopyrroloquinoxalines, and piperazinopyridopyrroloquinoxalines were prepared and evaluated as 5-HT3 receptor ligands. The chemical modifications performed within these new series led to structure−activity relationships regarding both high affinity and selectivity for the 5-HT3 receptors that are in agreement with those established previously for the pyrrolothienopyrazine series. The best compound (8a) obtained in these new series is in the picomolar range of affinity for 5-HT3 receptors with a selectivity higher than 106. Four of the high-affinity 5-HT3 ligands (8a, 15a,b, and 16d) were selected in both the pyridopyrrolopyrazine and the pyrroloquinoxaline series and were characterized in vitro and in vivo as agonists or partial agonists. Compound 8a was also evaluated in the light/dark test where it showed potential anxiolytic-like activity at very low doses per os. |
doi_str_mv | 10.1021/jm960501o |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_79083615</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>79083615</sourcerecordid><originalsourceid>FETCH-LOGICAL-a305t-3d2768ed362eee411bf8cf9d829c6c7475edea84a61a5db1ac0e6a932e17a6133</originalsourceid><addsrcrecordid>eNp1ks-O0zAQxi3EaikLBx4AyQfgRIr_JE5yXHaXXUQFFS1crakzWVzSONhJteUV96XWoVUFB2TJY833-2ak8RDygrMpZ4K_W29KxTLG3SMy4ZlgSVqw9DGZMCZEIpSQT8jTENaMMcmFPCWnJY8nyyfk_rPbYkOhregCGzS93SKdg-8tNPT81rU29IG6mmbJzVLSr2iw650PUyqmdLFr-x8YbPjjf29d426ticarLTQD9Na1o3VuO_Tw27au23lbjbePaAxjEsPbf4lR-zXE9x00e3ms_p8if4PPyEkNTcDnh3hGvn24Wl7cJLMv1x8vzmcJSJb1iaxErgqspBKImHK-qgtTl1UhSqNMnuYZVghFCopDVq04GIYKSimQ5zEn5Rl5s6_b-dgfQ683NhhsGmjRDUHnJSuk4lkEXx7AYbXBSnfebsDv9GH6UX910CHEsdUeWmPDEROqKFU69kv2WPwLvDvK4H9qlcs808v5Qs-KT_klu-T6e-Rf73kwQa_d4Ns4Dc2ZHndFH3dFPgCRjrT4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>79083615</pqid></control><display><type>article</type><title>Novel and Selective Partial Agonists of 5-HT3 Receptors. 2. Synthesis and Biological Evaluation of Piperazinopyridopyrrolopyrazines, Piperazinopyrroloquinoxalines, and Piperazinopyridopyrroloquinoxalines</title><source>American Chemical Society:Jisc Collections:American Chemical Society Read & Publish Agreement 2022-2024 (Reading list)</source><creator>Prunier, Hervé ; Rault, Sylvain ; Lancelot, Jean-Charles ; Robba, Max ; Renard, Pierre ; Delagrange, Philippe ; Pfeiffer, Bruno ; Caignard, Daniel-Henri ; Misslin, René ; Hamon, Michel</creator><creatorcontrib>Prunier, Hervé ; Rault, Sylvain ; Lancelot, Jean-Charles ; Robba, Max ; Renard, Pierre ; Delagrange, Philippe ; Pfeiffer, Bruno ; Caignard, Daniel-Henri ; Misslin, René ; Hamon, Michel</creatorcontrib><description>In continuation of our previous work on piperazinopyrrolothienopyrazine derivatives, three series of piperazinopyridopyrrolopyrazines, piperazinopyrroloquinoxalines, and piperazinopyridopyrroloquinoxalines were prepared and evaluated as 5-HT3 receptor ligands. The chemical modifications performed within these new series led to structure−activity relationships regarding both high affinity and selectivity for the 5-HT3 receptors that are in agreement with those established previously for the pyrrolothienopyrazine series. The best compound (8a) obtained in these new series is in the picomolar range of affinity for 5-HT3 receptors with a selectivity higher than 106. Four of the high-affinity 5-HT3 ligands (8a, 15a,b, and 16d) were selected in both the pyridopyrrolopyrazine and the pyrroloquinoxaline series and were characterized in vitro and in vivo as agonists or partial agonists. Compound 8a was also evaluated in the light/dark test where it showed potential anxiolytic-like activity at very low doses per os.</description><identifier>ISSN: 0022-2623</identifier><identifier>EISSN: 1520-4804</identifier><identifier>DOI: 10.1021/jm960501o</identifier><identifier>PMID: 9191957</identifier><identifier>CODEN: JMCMAR</identifier><language>eng</language><publisher>Washington, DC: American Chemical Society</publisher><subject>Animals ; Anti-Anxiety Agents - chemical synthesis ; Anti-Anxiety Agents - metabolism ; Anti-Anxiety Agents - therapeutic use ; Anxiety - drug therapy ; Anxiety - etiology ; Biological and medical sciences ; Cattle ; Cell Membrane - metabolism ; Corpus Striatum - metabolism ; Darkness ; Frontal Lobe - metabolism ; Guanidine ; Guanidines - metabolism ; Hippocampus - metabolism ; Light ; Male ; Medical sciences ; Molecular Structure ; Neuropharmacology ; Neurotransmitters. Neurotransmission. Receptors ; Pharmacology. Drug treatments ; Pyrazines - chemical synthesis ; Pyrazines - metabolism ; Pyrazines - therapeutic use ; Pyridines - chemical synthesis ; Pyridines - metabolism ; Pyridines - therapeutic use ; Rats ; Receptors, Serotonin - metabolism ; Receptors, Serotonin, 5-HT3 ; Serotonin Receptor Agonists - chemical synthesis ; Serotonin Receptor Agonists - metabolism ; Serotonin Receptor Agonists - therapeutic use ; Serotoninergic system ; Structure-Activity Relationship ; Swine</subject><ispartof>Journal of medicinal chemistry, 1997-06, Vol.40 (12), p.1808-1819</ispartof><rights>Copyright © 1997 American Chemical Society</rights><rights>1997 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2689643$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9191957$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Prunier, Hervé</creatorcontrib><creatorcontrib>Rault, Sylvain</creatorcontrib><creatorcontrib>Lancelot, Jean-Charles</creatorcontrib><creatorcontrib>Robba, Max</creatorcontrib><creatorcontrib>Renard, Pierre</creatorcontrib><creatorcontrib>Delagrange, Philippe</creatorcontrib><creatorcontrib>Pfeiffer, Bruno</creatorcontrib><creatorcontrib>Caignard, Daniel-Henri</creatorcontrib><creatorcontrib>Misslin, René</creatorcontrib><creatorcontrib>Hamon, Michel</creatorcontrib><title>Novel and Selective Partial Agonists of 5-HT3 Receptors. 2. Synthesis and Biological Evaluation of Piperazinopyridopyrrolopyrazines, Piperazinopyrroloquinoxalines, and Piperazinopyridopyrroloquinoxalines</title><title>Journal of medicinal chemistry</title><addtitle>J. Med. Chem</addtitle><description>In continuation of our previous work on piperazinopyrrolothienopyrazine derivatives, three series of piperazinopyridopyrrolopyrazines, piperazinopyrroloquinoxalines, and piperazinopyridopyrroloquinoxalines were prepared and evaluated as 5-HT3 receptor ligands. The chemical modifications performed within these new series led to structure−activity relationships regarding both high affinity and selectivity for the 5-HT3 receptors that are in agreement with those established previously for the pyrrolothienopyrazine series. The best compound (8a) obtained in these new series is in the picomolar range of affinity for 5-HT3 receptors with a selectivity higher than 106. Four of the high-affinity 5-HT3 ligands (8a, 15a,b, and 16d) were selected in both the pyridopyrrolopyrazine and the pyrroloquinoxaline series and were characterized in vitro and in vivo as agonists or partial agonists. Compound 8a was also evaluated in the light/dark test where it showed potential anxiolytic-like activity at very low doses per os.</description><subject>Animals</subject><subject>Anti-Anxiety Agents - chemical synthesis</subject><subject>Anti-Anxiety Agents - metabolism</subject><subject>Anti-Anxiety Agents - therapeutic use</subject><subject>Anxiety - drug therapy</subject><subject>Anxiety - etiology</subject><subject>Biological and medical sciences</subject><subject>Cattle</subject><subject>Cell Membrane - metabolism</subject><subject>Corpus Striatum - metabolism</subject><subject>Darkness</subject><subject>Frontal Lobe - metabolism</subject><subject>Guanidine</subject><subject>Guanidines - metabolism</subject><subject>Hippocampus - metabolism</subject><subject>Light</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Molecular Structure</subject><subject>Neuropharmacology</subject><subject>Neurotransmitters. Neurotransmission. Receptors</subject><subject>Pharmacology. Drug treatments</subject><subject>Pyrazines - chemical synthesis</subject><subject>Pyrazines - metabolism</subject><subject>Pyrazines - therapeutic use</subject><subject>Pyridines - chemical synthesis</subject><subject>Pyridines - metabolism</subject><subject>Pyridines - therapeutic use</subject><subject>Rats</subject><subject>Receptors, Serotonin - metabolism</subject><subject>Receptors, Serotonin, 5-HT3</subject><subject>Serotonin Receptor Agonists - chemical synthesis</subject><subject>Serotonin Receptor Agonists - metabolism</subject><subject>Serotonin Receptor Agonists - therapeutic use</subject><subject>Serotoninergic system</subject><subject>Structure-Activity Relationship</subject><subject>Swine</subject><issn>0022-2623</issn><issn>1520-4804</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><recordid>eNp1ks-O0zAQxi3EaikLBx4AyQfgRIr_JE5yXHaXXUQFFS1crakzWVzSONhJteUV96XWoVUFB2TJY833-2ak8RDygrMpZ4K_W29KxTLG3SMy4ZlgSVqw9DGZMCZEIpSQT8jTENaMMcmFPCWnJY8nyyfk_rPbYkOhregCGzS93SKdg-8tNPT81rU29IG6mmbJzVLSr2iw650PUyqmdLFr-x8YbPjjf29d426ticarLTQD9Na1o3VuO_Tw27au23lbjbePaAxjEsPbf4lR-zXE9x00e3ms_p8if4PPyEkNTcDnh3hGvn24Wl7cJLMv1x8vzmcJSJb1iaxErgqspBKImHK-qgtTl1UhSqNMnuYZVghFCopDVq04GIYKSimQ5zEn5Rl5s6_b-dgfQ683NhhsGmjRDUHnJSuk4lkEXx7AYbXBSnfebsDv9GH6UX910CHEsdUeWmPDEROqKFU69kv2WPwLvDvK4H9qlcs808v5Qs-KT_klu-T6e-Rf73kwQa_d4Ns4Dc2ZHndFH3dFPgCRjrT4</recordid><startdate>19970606</startdate><enddate>19970606</enddate><creator>Prunier, Hervé</creator><creator>Rault, Sylvain</creator><creator>Lancelot, Jean-Charles</creator><creator>Robba, Max</creator><creator>Renard, Pierre</creator><creator>Delagrange, Philippe</creator><creator>Pfeiffer, Bruno</creator><creator>Caignard, Daniel-Henri</creator><creator>Misslin, René</creator><creator>Hamon, Michel</creator><general>American Chemical Society</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>19970606</creationdate><title>Novel and Selective Partial Agonists of 5-HT3 Receptors. 2. Synthesis and Biological Evaluation of Piperazinopyridopyrrolopyrazines, Piperazinopyrroloquinoxalines, and Piperazinopyridopyrroloquinoxalines</title><author>Prunier, Hervé ; Rault, Sylvain ; Lancelot, Jean-Charles ; Robba, Max ; Renard, Pierre ; Delagrange, Philippe ; Pfeiffer, Bruno ; Caignard, Daniel-Henri ; Misslin, René ; Hamon, Michel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a305t-3d2768ed362eee411bf8cf9d829c6c7475edea84a61a5db1ac0e6a932e17a6133</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Animals</topic><topic>Anti-Anxiety Agents - chemical synthesis</topic><topic>Anti-Anxiety Agents - metabolism</topic><topic>Anti-Anxiety Agents - therapeutic use</topic><topic>Anxiety - drug therapy</topic><topic>Anxiety - etiology</topic><topic>Biological and medical sciences</topic><topic>Cattle</topic><topic>Cell Membrane - metabolism</topic><topic>Corpus Striatum - metabolism</topic><topic>Darkness</topic><topic>Frontal Lobe - metabolism</topic><topic>Guanidine</topic><topic>Guanidines - metabolism</topic><topic>Hippocampus - metabolism</topic><topic>Light</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Molecular Structure</topic><topic>Neuropharmacology</topic><topic>Neurotransmitters. Neurotransmission. Receptors</topic><topic>Pharmacology. Drug treatments</topic><topic>Pyrazines - chemical synthesis</topic><topic>Pyrazines - metabolism</topic><topic>Pyrazines - therapeutic use</topic><topic>Pyridines - chemical synthesis</topic><topic>Pyridines - metabolism</topic><topic>Pyridines - therapeutic use</topic><topic>Rats</topic><topic>Receptors, Serotonin - metabolism</topic><topic>Receptors, Serotonin, 5-HT3</topic><topic>Serotonin Receptor Agonists - chemical synthesis</topic><topic>Serotonin Receptor Agonists - metabolism</topic><topic>Serotonin Receptor Agonists - therapeutic use</topic><topic>Serotoninergic system</topic><topic>Structure-Activity Relationship</topic><topic>Swine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Prunier, Hervé</creatorcontrib><creatorcontrib>Rault, Sylvain</creatorcontrib><creatorcontrib>Lancelot, Jean-Charles</creatorcontrib><creatorcontrib>Robba, Max</creatorcontrib><creatorcontrib>Renard, Pierre</creatorcontrib><creatorcontrib>Delagrange, Philippe</creatorcontrib><creatorcontrib>Pfeiffer, Bruno</creatorcontrib><creatorcontrib>Caignard, Daniel-Henri</creatorcontrib><creatorcontrib>Misslin, René</creatorcontrib><creatorcontrib>Hamon, Michel</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Prunier, Hervé</au><au>Rault, Sylvain</au><au>Lancelot, Jean-Charles</au><au>Robba, Max</au><au>Renard, Pierre</au><au>Delagrange, Philippe</au><au>Pfeiffer, Bruno</au><au>Caignard, Daniel-Henri</au><au>Misslin, René</au><au>Hamon, Michel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Novel and Selective Partial Agonists of 5-HT3 Receptors. 2. Synthesis and Biological Evaluation of Piperazinopyridopyrrolopyrazines, Piperazinopyrroloquinoxalines, and Piperazinopyridopyrroloquinoxalines</atitle><jtitle>Journal of medicinal chemistry</jtitle><addtitle>J. Med. Chem</addtitle><date>1997-06-06</date><risdate>1997</risdate><volume>40</volume><issue>12</issue><spage>1808</spage><epage>1819</epage><pages>1808-1819</pages><issn>0022-2623</issn><eissn>1520-4804</eissn><coden>JMCMAR</coden><abstract>In continuation of our previous work on piperazinopyrrolothienopyrazine derivatives, three series of piperazinopyridopyrrolopyrazines, piperazinopyrroloquinoxalines, and piperazinopyridopyrroloquinoxalines were prepared and evaluated as 5-HT3 receptor ligands. The chemical modifications performed within these new series led to structure−activity relationships regarding both high affinity and selectivity for the 5-HT3 receptors that are in agreement with those established previously for the pyrrolothienopyrazine series. The best compound (8a) obtained in these new series is in the picomolar range of affinity for 5-HT3 receptors with a selectivity higher than 106. Four of the high-affinity 5-HT3 ligands (8a, 15a,b, and 16d) were selected in both the pyridopyrrolopyrazine and the pyrroloquinoxaline series and were characterized in vitro and in vivo as agonists or partial agonists. Compound 8a was also evaluated in the light/dark test where it showed potential anxiolytic-like activity at very low doses per os.</abstract><cop>Washington, DC</cop><pub>American Chemical Society</pub><pmid>9191957</pmid><doi>10.1021/jm960501o</doi><tpages>12</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0022-2623 |
ispartof | Journal of medicinal chemistry, 1997-06, Vol.40 (12), p.1808-1819 |
issn | 0022-2623 1520-4804 |
language | eng |
recordid | cdi_proquest_miscellaneous_79083615 |
source | American Chemical Society:Jisc Collections:American Chemical Society Read & Publish Agreement 2022-2024 (Reading list) |
subjects | Animals Anti-Anxiety Agents - chemical synthesis Anti-Anxiety Agents - metabolism Anti-Anxiety Agents - therapeutic use Anxiety - drug therapy Anxiety - etiology Biological and medical sciences Cattle Cell Membrane - metabolism Corpus Striatum - metabolism Darkness Frontal Lobe - metabolism Guanidine Guanidines - metabolism Hippocampus - metabolism Light Male Medical sciences Molecular Structure Neuropharmacology Neurotransmitters. Neurotransmission. Receptors Pharmacology. Drug treatments Pyrazines - chemical synthesis Pyrazines - metabolism Pyrazines - therapeutic use Pyridines - chemical synthesis Pyridines - metabolism Pyridines - therapeutic use Rats Receptors, Serotonin - metabolism Receptors, Serotonin, 5-HT3 Serotonin Receptor Agonists - chemical synthesis Serotonin Receptor Agonists - metabolism Serotonin Receptor Agonists - therapeutic use Serotoninergic system Structure-Activity Relationship Swine |
title | Novel and Selective Partial Agonists of 5-HT3 Receptors. 2. Synthesis and Biological Evaluation of Piperazinopyridopyrrolopyrazines, Piperazinopyrroloquinoxalines, and Piperazinopyridopyrroloquinoxalines |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T06%3A53%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Novel%20and%20Selective%20Partial%20Agonists%20of%205-HT3%20Receptors.%202.%20Synthesis%20and%20Biological%20Evaluation%20of%20Piperazinopyridopyrrolopyrazines,%20Piperazinopyrroloquinoxalines,%20and%20Piperazinopyridopyrroloquinoxalines&rft.jtitle=Journal%20of%20medicinal%20chemistry&rft.au=Prunier,%20Herv%C3%A9&rft.date=1997-06-06&rft.volume=40&rft.issue=12&rft.spage=1808&rft.epage=1819&rft.pages=1808-1819&rft.issn=0022-2623&rft.eissn=1520-4804&rft.coden=JMCMAR&rft_id=info:doi/10.1021/jm960501o&rft_dat=%3Cproquest_pubme%3E79083615%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-a305t-3d2768ed362eee411bf8cf9d829c6c7475edea84a61a5db1ac0e6a932e17a6133%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=79083615&rft_id=info:pmid/9191957&rfr_iscdi=true |